

# Bioassay-Guided Isolation and Identification of Desacetylmicrocolin B from *Lyngbya cf. polychroa*

## Authors

Theresa Meickle<sup>1,2</sup>, Susan Matthew<sup>3</sup>, Cliff Ross<sup>4</sup>, Hendrik Luesch<sup>3</sup>, Valerie Paul<sup>1</sup>

## Affiliations

<sup>1</sup> Smithsonian Marine Station at Fort Pierce, Fort Pierce, Florida, USA

<sup>2</sup> Florida Atlantic University, Boca Raton, Florida, USA

<sup>3</sup> Department of Medicinal Chemistry, University of Florida, Gainesville, Florida, USA

<sup>4</sup> University of North Florida, Jacksonville, Florida, USA

## Key words

- cyanobacteria
- Oscillatoriaceae
- *Lyngbya polychroa*
- microcolins
- cytotoxins

## Abstract

▼  
Bioassay-guided fractionation of a non-polar extract of *Lyngbya cf. polychroa* resulted in the isolation of the cytotoxic desacetylmicrocolin B (**1**) as well as the known compounds microcolins A (**2**) and B (**3**). Compound **1** was found to inhibit the growth of HT-29 colorectal adenocarcinoma and IMR-32 neuroblastoma cells with half maximal inhibitory concentration (IC<sub>50</sub>) values of 14 nM for both cancer cell types. Microcolins A and B

were found to have little activity against two strains of the marine fungus *Dendryphiella salina* with LD<sub>50</sub> values above 200 µg/mL. Compounds **1**, **2**, and **3** were obtained by reverse-phase chromatography and their structures were determined by NMR and MS. In this paper we report the isolation, identification, and biological activity of **1**.

**Supporting information** available online at <http://www.thieme-connect.de/ejournals/toc/plantamedica>

## Introduction

▼  
Cyanobacteria have become well-known as a rich source of biologically active natural products, including polyketide macrolides, linear and cyclic peptides, and alkaloids [1]. In particular, cyanobacteria are prolific sources of biologically active peptides with highly modified amino acid residues, including microcystins, nodularin, and microcolins. These compounds show an array of biological activities such as cytotoxicity, hepatotoxicity, neurotoxicity, antibacterial, and antifungal activities [2,3]. This paper describes the isolation, identification and biological activity of the microcolin B analogue desacetylmicrocolin B (**1**) as well as the known natural products microcolins A (**2**) and B (**3**) (○ Fig. 1). Microcolins A and B were originally isolated from a Venezuelan collection of the cyanobacterium *Lyngbya majuscula* [4]. Since their initial isolation, these compounds have been well studied as potent immunosuppressive lipopeptides [5–13]. Here we report the isolation, identification, and biological activity of desacetylmicrocolin B (**1**).

## Materials and Methods

### General experimental procedures

▼  
IR data was obtained on a Perkin Elmer Spectrum 100 FT-IR spectrometer and optical rotations were measured on a Perkin Elmer model 343 polarimeter. <sup>1</sup>H- and 2D-NMR spectra for **1** were recorded in CDCl<sub>3</sub> on a Bruker Avance II 600 MHz spectrometer equipped with a 1-mm triple-resonance high-temperature superconducting cryogenic probe using residual solvent signals ( $\delta_{\text{H}} = 7.24$ ,  $\delta_{\text{C}} = 77.0$  for chloroform). For microcolins A (**2**) and B (**3**), <sup>1</sup>H- and 2D-NMR spectra were recorded in CDCl<sub>3</sub> on a JEOL-600 operating at 600 MHz using residual solvent signals for reference ( $\delta_{\text{H}} = 7.24$ ,  $\delta_{\text{C}} = 77.0$  for chloroform). LC-MS/MS analysis was performed using an Agilent 1100 HPLC system equipped with a Thermo Finnigan LCQ Advantage ion trap mass spectrometer via an ESI (+) interface. HR-MS data were obtained using an Agilent LC-TOF mass spectrometer equipped with an APCI/ESI multimode ion source detector.

### Collection

The marine cyanobacterium, *Lyngbya* sp., was collected in August 2005 by hand while scuba diving off the coast of Hollywood, Florida (26°01.1414'N, 80°05.9973'W) at a depth of 7.1 m. This species grew as red, hair-like tufts and was collected in a

received Nov. 21, 2008  
revised March 3, 2009  
accepted March 26, 2009

## Bibliography

DOI 10.1055/s-0029-1185675

Published online May 8, 2009

Planta Med 2009; 75:

1427–1430 © Georg Thieme  
Verlag KG Stuttgart · New York ·  
ISSN 0032-0943

## Correspondence

Dr. Valerie Paul

Smithsonian Marine Station at  
Fort Pierce  
701 Seaway Drive  
Fort Pierce FL 34949  
USA  
Phone: + 1 772 462 0982  
Fax: + 1 772 461 8154  
paul@si.edu




Fig. 1 Structures of compounds 1, 2, and 3.

large zip-lock plastic bag filled with seawater and transported back to the Smithsonian Marine Station in a cooler filled with seawater. At the Smithsonian Marine Station the sample was drained of seawater, frozen at  $-20^{\circ}\text{C}$ , and subsequently freeze dried. Voucher specimens (VPLP8\_17\_05) were preserved in 5% formalin/seawater and are retained at the Smithsonian Marine Station. Identification of the *Lyngbya* sp. was based on microscopic examination. Samples were identified based on morphological characteristics according to Littler and Littler [14]. The specimen most closely resembled *Lyngbya polychroa* (Meneghini) Rabenhorst 1847 with filament widths of  $38.6 \pm 2.5 \mu\text{m}$ , cell widths of  $29.9 \pm 2.3 \mu\text{m}$ , and cell lengths of  $4.2 \pm 0.4 \mu\text{m}$ .

### Extraction and isolation

The freeze-dried cyanobacterium (195.1 g dry wt.) was extracted with 1:1 MeOH/EtOAc ( $3 \times 1 \text{ L}$ , 24 h each). The filtered extract was combined and concentrated under reduced pressure to yield 52.6 g of crude extract. The crude 1:1 MeOH/EtOAc extract (6 g) was fractionated by three combined separations on a C18 flash column ( $54 \mu\text{m}$ ,  $2.5 \times 10 \text{ cm}$ ; Varian Mega Bond Elut, 60 mL) using a step gradient of MeOH-H<sub>2</sub>O-acetone 20:80:0, 30:70:0, 40:60:0, 50:50:0, 75:25:0, 100:0:0, and 0:0:100 (200 mL each). The active fractions, 5 and 6 (75:25 MeOH/H<sub>2</sub>O and 100% MeOH), were separated by bioassay-guided (cytotoxicity) fractionation. Fraction 5 (55 mg) was separated by RP HPLC (Econosil C18;  $10 \mu\text{m}$ ,  $1 \times 25 \text{ cm}$ , absorbance 254 nm, flow rate 2.0 mL/min) with a gradient of 50:50 MeOH/H<sub>2</sub>O to 76:24 MeOH/H<sub>2</sub>O over 15 min and then from 76:24 MeOH/H<sub>2</sub>O over 30 min to give nine fractions (5a–i). Fraction 5g ( $t_{\text{R}}$  30.3 min, 9.8 mg) was shown to be the known compound microcolin A (2). Fraction 6 (239.5 mg) was separated by RP HPLC on Econosil C18 column with 9:1 MeOH/H<sub>2</sub>O to give fourteen fractions (6a–n). Fraction 6b ( $t_{\text{R}}$  17.6 min, 10.8 mg) was shown to be the known compound microcolin A (2). Fraction 6d ( $t_{\text{R}}$  24.2 min, 11.2 mg) was the known compound microcolin B (3). Fraction 6c ( $t_{\text{R}}$  19.9 min, 4.8 mg) was further separated by RP HPLC on Econosil C18 column with 85:15 MeOH/H<sub>2</sub>O to give three fractions (6c1–6c3). Fraction 6c2 was further separated by RP HPLC on Econosil C18 column with 3:1 ACN/H<sub>2</sub>O to give eleven fractions (6c2a–6c2k). Fraction 6c2i ( $t_{\text{R}}$  24.8 min, 1.7 mg) was identified as desacetylmicrocolin B (1). *Desacetylmicrocolin B* (1): Yield: 1.7 mg; Colorless oil;  $[\alpha]_{\text{D}}^{20}$ :  $-193$  ( $c$  0.01, CH<sub>3</sub>OH); IR:  $\nu_{\text{max}}$  = 2959, 2090, 1729, 1650  $\text{cm}^{-1}$ ; positive ESI-MS:  $m/z$  (rel. int.) = 712 [M + Na]<sup>+</sup> (100), 690 [M + H]<sup>+</sup> (4), 496 (2), 478 (18), 383 (10), 365 (92), 282 (44), 254 (4), 211 (46), 155 (2), 100 (34); HR-ESI-MS:  $m/z$  = 712.4614 [M + Na]<sup>+</sup> (calcd. for C<sub>37</sub>H<sub>63</sub>N<sub>5</sub>O<sub>7</sub>Na: 712.4625); NMR data see Table 1.

### Conversion of microcolin B to desacetylmicrocolin B

Microcolin B was converted to desacetylmicrocolin B in order to compare the stereochemistry of the isolated desacetylmicrocolin B with that of microcolin B. This was done by reacting 4.1 mg of microcolin B dissolved in 1.8 mL of ethanol with 200  $\mu\text{L}$  of 5% NaHCO<sub>3</sub> (in water) for 4 hours with constant stirring. A dilute basic solution was used because degradation of the molecule occurred at higher concentrations of base. The reaction was quenched by adding 2 N HCl dropwise to the solution until it was neutralized. The reaction solution was then dried and the salt removed through liquid-liquid partition between ethyl acetate and water. Finally, the converted product was separated by RP HPLC (Econosil C18;  $10 \mu\text{m}$ , absorbance 254 nm, flow rate 2.0 mL/min) with a gradient of 3:1 MeOH/H<sub>2</sub>O for 25 min and then 3:1 MeOH/H<sub>2</sub>O to 100% MeOH over 10 min to give five fractions. Fraction 2 ( $t_{\text{R}}$  27.8 min, 0.5 mg) was identified as the converted product, desacetylmicrocolin B. The optical rotation of the converted product was  $[\alpha]_{\text{D}}^{20}$ :  $-129$  ( $c$  0.01, CH<sub>3</sub>OH). The <sup>1</sup>H-NMR data for the product were identical with those for compound 1 (Table 1).

### Marine antifungal assay

Microcolins A and B (purity >95%) were assayed against two strains of the marine fungus *Dendryphiella salina* as previously described [15,16]. Desacetylmicrocolin B was not tested in this assay due to limited amounts of material. This saprophytic fungus has been linked to disease among marine algae and seagrasses [17,18]. Therefore, inhibition of the growth of this fungus may indicate a possible ecological role of the compounds microcolins A and B. The pure compounds were dissolved in methanol and incorporated into YPM media (0.25% yeast, 0.25% peptone, 0.50% mannitol, 1 L seawater, 16 g agar) at a range of concentrations from 6.25  $\mu\text{g}/\text{mL}$  to 200  $\mu\text{g}/\text{mL}$ . Six hundred microliters of the treated YPM media and controls (agar and 5% methanol) were poured into 24-well plates. *D. salina* was then inoculated into the center of each well, and 12 replicates were run for each concentration. When the growth of the fungus in the control wells covered 100% of the agar, approximately 72 h later, the treated wells were scored as percent of growth relative to the controls. The known antifungal compound, amphotericin B (Sigma; 80% purity), was tested in the same way (except that 3 replicates were tested for each concentration) and was found to give 100% inhibition at concentrations of 3.13  $\mu\text{g}/\text{mL}$  or higher.

### Cytotoxicity assay

Cell viability was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. Cancer cells (ATCC) were plated in 96-well plates (HT-29, 10000 cells; IMR-32, 30000 cells), and after 24 h were treated with various concentrations of compounds 1, 2, or 3 (purity >95%) or solvent control (1% EtOH). After 48 h of incubation, cell viability was measured using MTT according to the manufacturer's instructions (Promega). Assays were run in duplicate and dose-response curves were generated using XLfit Excel (ID Business Solutions, Ltd.). Largazole (purity >95%), which has been shown to inhibit the cell lines HT29 (GI<sub>50</sub> 12 nM) and IMR-32 (GI<sub>50</sub> 16 nM), served as a positive control [19].

### Supporting information

Original spectra of compound 1 and of the converted product are available as Supporting Information.


**Table 1** NMR data for desacetylmicrocolin B in CDCl<sub>3</sub> (600 MHz).

Position	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , mult.	HMBC	Position	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , mult.	HMBC
1	–	169.9, qC	–	23	4.07 m	67.2, CH	21, 24
2	6.04 dd (6.2, 1.4)	125.3, CH	1	24	1.03 d (6.2)	14.0, CH <sub>3</sub>	–
3	7.21 dd (6.2, 2.0)	153.8, CH	1	25	4.01 m	–	–
4	4.74 m	58.0, CH	2, 3, 6	27	–	171.4, qC	–
5	–	–	–	28	5.23 t (15.8, 7.5)	53.8, CH	27, 30, 31, 34, 35
6	1.43 d (6.2)	17.0, CH <sub>3</sub>	–	29	–	–	–
7	–	171.7, qC	–	30a	1.66 m	35.9, CH <sub>2</sub>	–
8	5.43 dd (8.1, 4.9)	59.5, CH	7, 9, 10, 11	30b	1.56 m	–	–
9a	2.37 m	28.7, CH <sub>2</sub>	–	31	1.39 m	29.8, CH	–
9b	1.85 m	–	–	32	0.84 d (6.2)	21.6, CH <sub>3</sub>	30
10a	2.04 m	24.6, CH <sub>2</sub>	–	33	0.91 d (6.9)	23.0, CH <sub>3</sub>	–
10b	1.94 m	–	–	34	2.93 s	30.4, CH <sub>3</sub>	28, 35
11a	3.75 m	47.9, CH <sub>2</sub>	–	35	–	178.2, qC	–
11b	3.78 m	–	–	36	2.81 m	33.6, CH	35, 37
12	–	–	–	37a	1.05 m	41.7, CH <sub>2</sub>	–
13	–	169.3, qC	–	37b	1.82 m	–	–
14	4.99 d (11.0)	59.2, CH	13, 16, 17, 19, 20	38	1.27 m	30.5, CH	–
15	–	–	–	39	1.25 m	35.8, CH <sub>2</sub>	–
16	2.25 m	27.0, CH	–	40	1.25 m	28.9, CH <sub>2</sub>	–
17	0.78 d (6.9)	18.3, CH <sub>3</sub>	–	41a	1.23 m	23.4, CH <sub>2</sub>	–
18	0.97 d (6.9)	18.7, CH <sub>3</sub>	–	41b	1.39 m	–	–
19	3.06 s	30.5, CH <sub>3</sub>	13, 14, 20	42	0.84 d (6.2)	14.0, CH <sub>3</sub>	40, 41
20	–	172.6, qC	–	43	1.09 d (6.9)	18.2, CH <sub>3</sub>	36
21	4.72 m	52.0, CH	23	44	0.80 d (6.9)	19.5, CH <sub>3</sub>	–
22	6.95 d (9.2)	–	27				

## Results and Discussion


Compound **1** was isolated as a colorless oil. The molecular formula of **1**, C<sub>37</sub>H<sub>63</sub>N<sub>5</sub>O<sub>7</sub>, was determined from the HR-ESI-MS pseudomolecular ion peak for [M + Na]<sup>+</sup>, *m/z* = 712.4614. The molecular formula defined by HR-ESI-MS indicated that compound **1** had two fewer carbon atoms than microcolin B (**3**). The IR spectrum for **1** showed the presence of an alkyl group (2959 cm<sup>-1</sup>), a carbonyl group (1729 cm<sup>-1</sup>), and a conjugated carbonyl group (1650 cm<sup>-1</sup>).

Comparison of the <sup>1</sup>H-NMR and COSY spectra of compound **1** to those of microcolins A (**2**) and B (**3**), isolated from the same fraction, further indicated that compound **1** was similar in structure to microcolin B. The lack of a singlet for the acetyl methyl group (1.98 ppm) suggested that this group was missing from compound **1**. This was confirmed by <sup>1</sup>H-NMR and COSY analysis, which showed the proton signal for the H-β of the threonine had shifted from 5.21 ppm in microcolin B to 4.07 ppm in compound **1** (● Fig. 1), suggesting the presence of a hydroxy instead of an acyloxy group. The proton signals for the alpha methine and methyl group of the threonine had shifted from 4.92 ppm to 4.72 ppm and from 1.15 ppm to 1.03 ppm, respectively, also indicating the loss of the acetate group. The presence of a broad singlet at 4.01 ppm confirmed that the acetate group attached to the beta carbon of the threonine had been replaced by a hydroxy group in compound **1**. The ESI-MS/MS fragmentation pattern (● Fig. 2) is also consistent with the proposed structure for **1**. The relative and absolute configuration of compound **1** was established after base hydrolysis of microcolin B (**3**) to desacetylmicrocolin B, followed by direct comparison of NMR data and optical rotations for the hydrolysis product with data for compound **1**. The <sup>1</sup>H-NMR data for authentic sample of microcolin B (**3**) and the hydrolysis product were identical and also comparable to those reported by Andrus et al. [5] for synthetic desacetylmicro-


**Fig. 2** ESI-MS/MS fragmentation pattern of **1**.

colin B, indicating that the relative configuration was the same. Furthermore, the same sign and also similar magnitude of the optical rotation with reported data for the microcolins [4,5] confirmed that the absolute configuration was also identical.

All compounds were tested for their ability to inhibit the growth of two solid tumor cell types: HT-29 colorectal adenocarcinoma and IMR-32 neuroblastoma cells. ● Fig. 3 and the results in ● Table 2 show that microcolin A had the most potent cytotoxicity in both tests, while microcolin B was less potent, and compound **1** was the least potent of the three molecules, yet still exhibited low-nanomolar activity (IC<sub>50</sub> 14 nM for each). In a synthetic study done by Mattern et al. [9], the octanoyl derivative of desacetylmicrocolin B was synthesized and tested in antitumor assays against A549 and P388 cell lines. The synthesized compound had ED<sub>50</sub> values of 5.0 μM in the A549 and 2.9 μM in the P388 assays. Comparison of these values to that of compound **1**, indicates that the methyl groups of the carbon chain are important for the activity of these molecules. Previously published activity results showed both microcolins A and B as potent immunosuppressive agents in a two-way murine mixed lymphocyte reaction with EC<sub>50</sub> and TC<sub>50</sub> values of 1.5 nM and 22.6 nM, respectively, for microcolin A and 42.7 nM and 191.0 nM, respectively, for microcolin B [4]. More recently, microcolin B has been shown as a potential



**Fig. 3** Effect of microcolins 1–3 on cancer cell viability. **A** HT-29 cells, **B** IMR-32 cells. Graphs show means + 1 SD (n = 2).



**Fig. 4** Effect of microcolins A (2) and B (3) on growth of two fungal strains of *Dendryphiella salina*. **A** Strain SIO, **B** Strain EBGJ. Bars represent means + 1 SE (n = 12).

**Table 2** Cytotoxicity data (IC<sub>50</sub>) for compounds 1, 2, and 3.

	HT-29	IMR-32
Microcolin A (2)	0.28 nM	0.31 nM
Microcolin B (3)	2.3 nM	7.7 nM
Desacetylmicrocolin B (1)	14 nM	14 nM

inhibitor of LFA-1/ICAM-1-mediated cell adhesion with an IC<sub>50</sub> value of 0.15 µM [11].

Microcolins A and B were tested for their ability to inhibit the growth of two strains of the marine fungus *Dendryphiella salina*. The purpose of this assay was to investigate a possible ecological role for the cytotoxic compounds produced by this cyanobacterium. The results of these tests are shown in **Fig. 4**. For both strains, the LD<sub>50</sub> values of microcolins A and B are above 200 µg/mL. These values are 10 to 100 times higher than their cytotoxicity values in the cancer cell lines. The antifungal activities of microcolins A and B are significantly lower than that of amphotericin B, a known antifungal compound, which produced 100% inhibition in this assay at concentrations as low as 3.13 µg/mL. These results show that microcolins A and B, although potent immunosuppressive and cytotoxic substances, do not exhibit significant antifungal properties.

## Acknowledgments

Funding was provided by the National Oceanic and Atmospheric Administration's ECOHAB Program (Project NA05NOS4781194), the Florida Sea Grant College Program with support from NOAA,

Office of Sea Grant, U.S. Department of Commerce, Grant No. NA06OAR4170014, and NIGMS grant P41GM086210. We are grateful for the use of the NMR spectrometer at Harbor Branch Oceanographic Institute at Florida Atlantic University and gratefully acknowledge NSF for funding through the External User Program of the National High Magnetic Field Laboratory, which supported NMR studies at the Advanced Magnetic Resonance Imaging and Spectroscopy facility at the University of Florida (UF). We thank Sarath Gunasekera, who provided many helpful suggestions on this research, and Jody Johnson for LC-MS/MS analysis (Department of Chemistry, UF). HR-MS analyses were performed at the UCR Mass Spectrometry Facility, Department of Chemistry, University of California at Riverside. This is contribution # 772 of the Smithsonian Marine Station of Fort Pierce.

## References

- Tan LT. Bioactive natural products from marine cyanobacteria for drug discovery. *Phytochemistry* 2007; 68: 954–979
- Burja AM, Banaigs B, Abou-Mansour E, Burgess JG, Wright PC. Marine cyanobacteria – a prolific source of natural products. *Tetrahedron* 2001; 57: 9347–9377
- Singh S, Kate BN, Banerjee UC. Bioactive compounds from cyanobacteria and microalgae: an overview. *Crit Rev Biotechnol* 2005; 25: 73–95
- Koehn FE, Longley R, Reed JK. Microcolins A and B, new immunosuppressive peptides from the blue-green alga *Lyngbya majuscula*. *J Nat Prod* 1992; 55: 613–619
- Andrus MB, Li W, Keyes RF. Synthesis of microcolin B, a potent new immunosuppressant using an efficient mixed imide formation reaction. *J Org Chem* 1997; 62: 5542–5549
- Decicco CP, Grover P. Total asymmetric synthesis of the potent immunosuppressive marine natural product microcolin A. *J Org Chem* 1996; 61: 3534–3541
- Koehn FE, McConnell OJ, Longley RE, Sennett SH, Reed JK. Analogues of the marine immunosuppressant microcolin A: preparation and biological activity. *J Med Chem* 1994; 37: 3181–3186
- Mandal AK, Hines J, Kuramochi K, Crews CM. Developing microcolin A analogs as biological probes. *Bioorg Med Chem Lett* 2005; 15: 4043–4047
- Mattern R-H, Gunasekera S, McConnell O. Synthetic studies of microcolin B. *Tetrahedron* 1996; 52: 425–434
- Mattern R-H, Gunasekera SP, McConnell OJ. Synthesis of microcolin analogs using trimethylsilylated lactams. *Tetrahedron Lett* 1997; 38: 2197–2200
- Takamatsu S, Nagle DG, Gerwick WH. Secondary metabolites from marine cyanobacteria and algae inhibit LFA-1/ICAM-1 mediated cell adhesion. *Planta Med* 2004; 70: 127–131
- Zhang L-H, Longley RE, Koehn FE. Antiproliferative and immunosuppressive properties of microcolin A, a marine-derived lipopeptide. *Life Sci* 1997; 60: 751–762
- Zhang L-H, Longley RE. Induction of apoptosis in mouse thymocytes by microcolin A and its synthetic analog. *Life Sci* 1999; 64: 1013–1028
- Littler DS, Littler MM. Caribbean reef plants. Washington, D.C.: Offshore Graphics; 2000: 447–479
- Kubaneck J, Jensen PR, Keifer PA, Sullards MC, Collins DO, Fenical W. Seaweed resistance to microbial attack: a targeted chemical defense against marine fungi. *Proc Natl Acad Sci USA* 2003; 100: 6916–6921
- Puglisi MP, Tan LT, Jensen PR, Fenical W. Capisterones A and B from the tropical green alga *Penicillus capitatus*: unexpected anti-fungal defenses targeting the marine pathogen *Lindra thalassiae*. *Tetrahedron* 2004; 60: 7035–7039
- Engel S, Puglisi MP, Jensen PR, Fenical W. Antimicrobial activities of extracts from tropical Atlantic marine plants against marine pathogens and saprophytes. *Mar Biol* 2006; 149: 991–1002
- Puglisi MP, Engel S, Jensen PR, Fenical W. Antimicrobial activities of extracts from Indo-Pacific marine plants against marine pathogens and saprophytes. *Mar Biol* 2007; 150: 531–540
- Taori K, Paul VJ, Luesch H. Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium *Symploca* sp. *J Am Chem Soc* 2008; 130: 1806–1807